LANGUAGE
Investors
First-Half 2022 Results
- €1,658 million in first-half 2022 sales, up 5.3% as published, stable on a like-for-like basis
- Q2 sales organic growth up 5.2% like-for-like, led by a strong growth of BIOFIRE® range as well as a good performance in clinical microbiology and industry applications
- Contributive operating income before non-recurring items reached €322 million, or 19.4% of sales for the first half of the year
- 2022 guidance slightly improved
- bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics
- Reinforced portfolio of solutions with new product launches
“bioMérieux achieved a solid performance in the first half of 2022, in line with its expectations, both in terms of top line and profitability. In addition, we made a major acquisition in the field of rapid antimicrobial susceptibility testing with Specific Diagnostics that reinforces our long-standing commitment to sustain antibiotic efficacy for future generations and fits perfectly with our existing solutions. Within a highly uncertain and inflationary environment, we do confirm our annual guidance, slightly adjusted upward. ”
